ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1608

The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease

Curtis Sobchak1, Shadi Akhtari2, Paula Harvey2, Dafna D Gladman3, Vinod Chandran4, Richard J. Cook5 and Lihi Eder6, 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 3Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Krembil Research Institute & University of Toronto, Toronto, ON, Canada, 5Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 6Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, psoriasis, Psoriatic arthritis, risk assessment and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with psoriatic disease (PsD) are at a high risk of developing cardiovascular events (CVE). The performance of clinical algorithms for cardiovascular risk stratification, such as the Framingham Risk Score (FRS), is sub-optimal in this patient population. The study aims were: 1) to assess whether subclinical atherosclerosis, as evaluated by carotid ultrasound, could predict future CVE in patients with PsD and 2) to determine whether incorporation of imaging data could improve the prediction of CVE beyond clinical cardiovascular algorithms.

Methods: Patients with PsD from a large longitudinal cohort underwent ultrasound assessment of the carotid artery at baseline. The extent of atherosclerosis was assessed using mean carotid intima media thickness (cIMT in µm) and total plaque area (TPA in cm2). Patients were followed according to a standardized protocol at 6-12 month intervals. Incident CVE that occurred following the ultrasound assessment were identified from the cohort database and through linkage with national hospitalization and death registries. A cardiologist reviewed the medical records related to each CVE and classified them to major CVE (myocardial infarction, stroke, revascularization or cardiovascular death) and minor CVE (angina, TIA, CHF exacerbation). The association between measures of carotid atherosclerosis and the risk of developing future CVE was evaluated using Cox proportional hazard models after adjusting for FRS categories.

Results: Overall, 607 patients with PsD (66.7% with PsA) were assessed and 37 patients developed incident CVE confirmed by the cardiologist (28 major CVE). Their mean age was 57.1 (SD 11.7) and 57.7% were males. 26% and 34.8% had unilateral and bilateral carotid plaques, respectively. The incidence rate of CVE was higher in patients with bilateral carotid plaques compared with unilateral/no plaques (3.96 vs. 0.54 events per 100 person years; p<0.001, Figure 1).

 In multivariable regression models, TPA (Hazard Ratio (HR) 2.20, 95% Confidence Interval (CI) 1.51, 3.22; p <0.001), mean cIMT (HR 1.21, 95% CI 1.08, 1.34; p<0.001) and bilateral carotid plaques (HR 2.89, 95% CI 1.07, 7.77, p=0.03) predicted incident CVE after controlling for FRS. The results were similar after restricting the analysis to patients with major CVE and after excluding patients with a history of CVE at baseline.

 

Conclusion: Patients with PsD with subclinical carotid atherosclerosis are more likely to develop future CVE. Carotid ultrasound could potentially improve the identification of patients with PsD who are at high cardiovascular risk.

 

Table 1- The association between subclinical atherosclerosis and incident cardiovascular events (N=607, 37 events) – Cox proportional hazard model

 

Univariate analysis

 

Adjusted for Framingham risk score

 

 

HR (95% CI)

P value

HR (95% CI)

P value

TPA

3.48 (2.54, 4.79)

<0.0001

2.20 (1.51, 3.22)

<0.0001

Mean IMT

1.37 (1.25, 1.51)

<0.0001

1.21 (1.08, 1.34)

0.0009

Max IMT

1.19 (1.12, 1.26)

<0.0001

1.11 (1.03, 1.19)

0.003

Plaques

Unilateral vs. none

Bilateral vs. none

0.84 (0.20, 3.50)

6.82 (2.64, 17.62)

0.81

<0.0001

0.57 (0.14, 2.38)

2.89 (1.07, 7.77)

0.44

0.03

CI- confidence interval, HR- hazard ratio, IMT- intima media thickness, TPA – total plaque area


Disclosure: C. Sobchak, None; S. Akhtari, None; P. Harvey, None; D. D. Gladman, None; V. Chandran, None; R. J. Cook, None; L. Eder, None.

To cite this abstract in AMA style:

Sobchak C, Akhtari S, Harvey P, Gladman DD, Chandran V, Cook RJ, Eder L. The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-value-of-carotid-ultrasound-in-cardiovascular-risk-stratification-in-patients-with-psoriatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-value-of-carotid-ultrasound-in-cardiovascular-risk-stratification-in-patients-with-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology